COCP
Cocrystal Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−4.21%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.07
From 52W high−34.71%
Volume16504.00
Market cap$19.74M
P/E (TTM)—
P/S (TTM)59.8x
Div yield—
Key dataNov 4, 2026
Open
$1.07
From 52W high
−34.71%
Volume
16504.00
Market cap
$19.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
47.8
MomentumView details →
1D Return
−4.21%
YTD Return
+4.19%
SummaryUpdated Jun 1, 2026
Cocrystal Pharma, Inc. (NASDAQ:COCP) is a biotechnology company founded in 2008 and publicly traded since 2012. The company is headquartered in Bothell, Washington, and specializes in discovering and developing antiviral therapeutic treatments for serious and chronic viral diseases. Cocrystal employs structure-based drug design technologies to create novel antiviral compounds, with a primary focus on treating hepatitis C virus, influenza, coronavirus, and norovirus infections. The company operates as a clinical-stage biopharmaceutical firm with several drug candidates in various stages of development.
Similar companies
Latest newsMore news →
Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b human challenge study evaluating CDI-988 as a potential preventive and treatment for norovirus infection.56d agoCocrystal Pharma, Inc. appointed Carol L. Brosgart as a director of the Company, effective August 12, 2026.79d ago